Latest / The Well-Built Life / The Intricacies of Apoptosis: The Dual Pathways Revealed
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:15Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:20Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:25Speaker 1: and let's dive in. Welcome to The Well-Built Life. where
- 0:28Speaker 1: we delve into the science and health of our bodies. Today,
- 0:32Speaker 1: we are tackling a critical piece of cellular biology that
- 0:35Speaker 1: shapes our understanding of health and disease, apoptosis. So, Thomas,
- 0:41Speaker 1: how do you see apoptosis playing a role in our
- 0:43Speaker 1: lives outside the science lab?
- 0:45Speaker 2: Absolutely, Rachel. Apoptosis might sound like a complex, niche term,
- 0:50Speaker 2: but it's crucial for maintaining our health. When we talk
- 0:53Speaker 2: about programmed cell death, We are talking about a series
- 0:56Speaker 2: of events that ensure our body gets rid of damaged
- 0:59Speaker 2: or unnecessary cells. Basically, it's nature's quality control system. What's
- 1:05Speaker 2: interesting is that it's tightly regulated and its dysfunction can
- 1:08Speaker 2: lead to some of our most vexing diseases like cancer.
- 1:12Speaker 2: Let's break down how it works into two main pathways,
- 1:15Speaker 2: intrinsic and extrinsic. Right.
- 1:18Speaker 1: And that's the crucial nuance here. Let's start with the
- 1:22Speaker 1: intrinsic pathway. which was first observed by Martin Raff and
- 1:25Speaker 1: colleagues back in the 1970s. They identified how internal stressors,
- 1:32Speaker 1: like DNA damage or hypoxia, can trigger the collapse of
- 1:35Speaker 1: the mitochondrial outer membrane, leading to the release of cytochrome C.
- 1:40Speaker 1: This release is like the final domino, setting off a
- 1:44Speaker 1: chain reaction in apoptosis.
- 1:46Speaker 2: Exactly. It's a fascinating mechanism. The key proteins in the
- 1:51Speaker 2: BCL2 family, Think of them as traffic controllers. Play a
- 1:55Speaker 2: central role. Backs and back, the pro-apoptotic proteins, control the
- 2:01Speaker 2: permeabilization of the mitochondrial membrane, whereas BCL-2 and BCL-XL are anti-apoptotic.
- 2:10Speaker 2: It's a bit like a seesaw. If the pro-apoptotic players
- 2:14Speaker 2: get the upper hand, the cell is likely to die.
- 2:17Speaker 2: But if the anti-apoptotic proteins dominate, they keep the cell alive. True.
- 2:24Speaker 1: And this interplay is really what makes apoptosis so complex.
- 2:29Speaker 1: In models where backs and back significantly outweigh BCL2, to
- 2:33Speaker 1: raise a 50% increase in cellular death. So, by understanding
- 2:39Speaker 1: these mechanisms, we can better appreciate the delicate balance that
- 2:43Speaker 1: keeps us healthy.
- 2:44Speaker 2: And that brings us to the extrinsic pathway. This one's
- 2:48Speaker 2: activated by external signals, specifically ligand binding to cell surface
- 2:52Speaker 2: receptors like ASRTNF, R1. When this happens, the formation of
- 2:58Speaker 2: the death-inducing signaling complex, DISC, kicks off, involving caspase 8
- 3:03Speaker 2: and 10. Again, we see a similar dynamic where these
- 3:06Speaker 2: caspases need to be activated to initiate apoptosis. In the 1990s,
- 3:11Speaker 2: the discovery of FOS and its ligand fossil solidified this pathway.
- 3:17Speaker 1: Fascinating, the extrinsic pathways activation isn't just limited to external insults,
- 3:23Speaker 1: it plays a significant role in the convergence of both pathways.
- 3:27Speaker 1: For instance, FAS can act as a double agent, initiating
- 3:31Speaker 1: a caspase cascade that amplifies the intrinsic pathways response. This
- 3:36Speaker 1: is another example of how the body ensures a coordinated
- 3:39Speaker 1: response to stress.
- 3:41Speaker 2: Exactly this convergence is what makes the intracellular signaling so complex.
- 3:46Speaker 2: But it's also a testament to the body's incredible complexity
- 3:50Speaker 2: and the layers of regulation that keep us healthy. By
- 3:53Speaker 2: understanding these intertwined pathways, researchers are starting to explore new
- 3:57Speaker 2: therapeutic avenues for diseases like cancer, where the dysregulation of
- 4:02Speaker 2: apoptosis plays a crucial role.
- 4:04Speaker 1: Indeed, it's not just about the mechanics either. From a
- 4:07Speaker 1: medical perspective, manipulating apoptosis could offer precision treatments for cancer, diabetes,
- 4:14Speaker 1: and even neurodegeneration. with new drugs targeting the specific proteins
- 4:18Speaker 1: in the BCL-2 family, we might be able to find
- 4:21Speaker 1: more personalized and effective therapies in the future.
- 4:24Speaker 2: That's the exciting part. The future of precision medicine depends
- 4:28Speaker 2: heavily on our ability to precisely control the apoptotic process.
- 4:33Speaker 2: Whether it's through enhancing natural apoptosis or preventing its unwanted dysregulation,
- 4:39Speaker 2: this is where the science of the future is headed.
- 4:42Speaker 1: All right, let's dive deeper into the intrinsic pathway and
- 4:45Speaker 1: its intricacies. Cellular stressors play a significant role here, right? Thomas,
- 4:51Speaker 1: how do these stressors affect mitochondrial function?
- 4:53Speaker 2: Exactly, Rachel. Think of cellular stressors like the body's equivalent
- 4:58Speaker 2: of a sudden power outage. Things like DNA damage, hypoxia,
- 5:02Speaker 2: or oncogene activation send signals that stress the cell, often
- 5:06Speaker 2: culminating in the release of cytochrome C from the mitochondrial
- 5:10Speaker 2: outer membrane, a critical step that triggers the BCL2 family
- 5:14Speaker 2: to respond.
- 5:15Speaker 1: Yes. And it's fascinating how that release triggers a cascade
- 5:18Speaker 1: of events. Let's break it down. How does mitochondrial outer
- 5:24Speaker 1: membrane permeabilization, MOP, fit into this picture?
- 5:28Speaker 2: Great question. MOP happens when the outer membrane of mitochondria
- 5:32Speaker 2: becomes more permeable, allowing cytochrome C to leak out. This
- 5:36Speaker 2: leakage is primarily controlled by BCL2 family proteins, with BACs
- 5:41Speaker 2: and BAC being the key players. BACs and BAC can
- 5:45Speaker 2: form channels in the mitochondrial membrane, allowing cytochrome C to
- 5:49Speaker 2: leak out.
- 5:50Speaker 1: And this is where the numbers come into play. Research
- 5:53Speaker 1: shows that BACs and BAC are highly effective in triggering apoptosis.
- 5:58Speaker 1: The chance of cellular death via MOMP increases by 50%
- 6:02Speaker 1: when BACs and BAC are active. How do these proteins
- 6:05Speaker 1: work together?
- 6:06Speaker 2: That's a great point. BACs and BAC are like the
- 6:09Speaker 2: cell's gatekeepers. They can exist in an active or inactive state.
- 6:14Speaker 2: When cellular stressors trigger the right conditions, backs and backs
- 6:18Speaker 2: switch to their active state, forming oligomers that create pores
- 6:22Speaker 2: in the mitochondrial membrane. This allows cytochrome C to escape,
- 6:26Speaker 2: initiating the formation of the apoptosome complex.
- 6:30Speaker 1: And this complex is essential because it leads to the
- 6:33Speaker 1: activation of caspases, right?
- 6:36Speaker 2: Absolutely. Once cytochrome C is free... It binds to APAF-1,
- 6:42Speaker 2: forming the apoptosome complex. This complex then activates caspase-9, which
- 6:49Speaker 2: in turn activates the downstream caspases like caspase-3 and negative-7.
- 6:55Speaker 2: These caspases start the process of dismantling the cell.
- 6:58Speaker 1: It's amazing how precise and intricate this system is. But
- 7:03Speaker 1: what happens when BCL2 family proteins are in higher levels?
- 7:07Speaker 1: How does that affect the process?
- 7:09Speaker 2: Good question. BCL2 family proteins have both pro-apoptotic and anti-apoptotic members.
- 7:17Speaker 2: BCL2 and BCLXL, for instance, are anti-apoptotic and can neutralize
- 7:23Speaker 2: the effects of BACs and BAC, so when their levels
- 7:26Speaker 2: are high, they can block the momp and prevent the
- 7:29Speaker 2: release of cytochrome C. This balance is crucial for fine,
- 7:33Speaker 2: tuning the cell's response to stress.
- 7:35Speaker 1: And this balance can vary between different cell types. Can't it?
- 7:40Speaker 1: It's fascinating how individualized apoptosis can be.
- 7:44Speaker 2: Precisely. Cellular response to stress is highly context-dependent. For instance,
- 7:50Speaker 2: in some scenarios, the activation of FASA key player in
- 7:53Speaker 2: the extrinsic pathway can be 20% more effective in inducing apoptosis,
- 7:59Speaker 2: as you mentioned data points from previous research. This shows
- 8:03Speaker 2: how both pathways and their interactions can significantly influence the
- 8:07Speaker 2: cell's fate.
- 8:08Speaker 1: So let's dive into the extrinsic pathway in more detail.
- 8:12Speaker 1: Imagine the ligand binding to a death receptor as the
- 8:14Speaker 1: first domino. It's a signal that something is amiss and
- 8:17Speaker 1: the cell must react.
- 8:19Speaker 2: Exactly. Think of it like a key fitting into a lock.
- 8:23Speaker 2: Once FASL binds to the FAS receptor on the cell surface,
- 8:26Speaker 2: it triggers a series of events that can lead to
- 8:29Speaker 2: cell death. That's the crucial moment that sets the stage
- 8:32Speaker 2: for the formation of the disk. Right.
- 8:35Speaker 1: And that's where things get interesting. The disk, or death,
- 8:38Speaker 1: inducing signaling complex is like a command center for these events.
- 8:43Speaker 1: It brings together procaspase-8 and sometimes procaspase-10 with the adapter
- 8:49Speaker 1: molecule FAD. This complex is pivotal for downstream signaling.
- 8:54Speaker 2: Precisely. The disk activates caspase-8 straight away. This isn't just
- 8:59Speaker 2: an isolated event, it's the beginning of a cascade that
- 9:02Speaker 2: can propagate the apoptotic signal. In fact, studies have shown
- 9:05Speaker 2: that FAAs through this pathway can be about 20% more
- 9:09Speaker 2: effective in inducing apoptosis compared to the intrinsic pathway in
- 9:13Speaker 2: some contexts.
- 9:14Speaker 1: That's wild when you look at the raw numbers. So
- 9:17Speaker 1: if FAS is such an effective trigger, why do we
- 9:20Speaker 1: even have the intrinsic pathway? It seems redundant.
- 9:23Speaker 2: Not at all. It's the interplay between these pathways that
- 9:27Speaker 2: defines the complexity and robustness of the apoptotic response. Take
- 9:31Speaker 2: a look at how BCL2 family proteins are involved. They
- 9:35Speaker 2: are like managers overseeing a symphony, making sure the right
- 9:38Speaker 2: signals are received and amplified. Absolutely. Think about it in
- 9:42Speaker 2: terms of historical figures, like Martin Raff and those who
- 9:46Speaker 2: first identified Bax and Back. These proteins play a central
- 9:50Speaker 2: role in modulating the intrinsic pathway. But, in the extrinsic pathway,
- 9:55Speaker 2: it's the engagement of caspase-8 that's the key. If we
- 10:00Speaker 2: look at the quantitative data, procaspase-8 is a bit like
- 10:04Speaker 2: a spark. Once lit, it sets off a chain reaction
- 10:07Speaker 2: in the cell.
- 10:08Speaker 1: Right. It's like a game of dominoes. The binding of
- 10:11Speaker 1: Facil-TefSAs starts the game, and once the disk forms, caspase-8
- 10:16Speaker 1: is activated almost instantly. This quick response can be critical
- 10:21Speaker 1: in certain scenarios, where a rapid cell death is needed.
- 10:24Speaker 2: That's it. And it's not just about speed, it's also
- 10:28Speaker 2: about efficacy. The 20% increase in induction of apoptosis by
- 10:33Speaker 2: FAS shows that this pathway can be more precise. But remember,
- 10:37Speaker 2: they are not mutually exclusive. They can work in tandem,
- 10:41Speaker 2: depending on the cellular context. True.
- 10:44Speaker 1: And that interplay is what makes understanding apoptosis such a
- 10:47Speaker 1: complex and fascinating field. It's about recognizing the unique roles
- 10:53Speaker 1: each pathway plays and how they can work together to
- 10:56Speaker 1: maintain cellular homeostasis. All right, let's explore the crosstalk between
- 11:01Speaker 1: pathways and the role of mitochondrial membrane potential more closely.
- 11:06Speaker 1: As we have seen, the intrinsic and extrinsic pathways can
- 11:09Speaker 1: work in concert to regulate apoptosis. But the dynamics are complex, right? Thomas?
- 11:16Speaker 2: Absolutely, Rachel. The mitochondrial membrane potential, MMP, is a critical
- 11:22Speaker 2: player here. When it drops, it's a clear sign that
- 11:25Speaker 2: MOMP is impending. This can amplify the extrinsic pathway when
- 11:30Speaker 2: the intrinsic mechanisms kick in. Right.
- 11:32Speaker 1: And that's the crucial nuance here. So, Thomas, what do
- 11:36Speaker 1: we make of this dynamic interplay? How does the membrane
- 11:40Speaker 1: potential actually influence the process?
- 11:43Speaker 2: Well, it's like a seesaw, you see. A healthy MMP
- 11:46Speaker 2: promotes cell survival by keeping BCL2 family proteins active. But
- 11:51Speaker 2: a drop in MMP triggers BACs and BAC activation, leading
- 11:55Speaker 2: to MOP and cytochrome C release. This can then activate
- 11:59Speaker 2: caspases from both intrinsic and extrinsic pathways, creating this complex
- 12:04Speaker 2: feedback loop.
- 12:05Speaker 1: Exactly. Which brings up an interesting contradiction. If the extrinsic
- 12:09Speaker 1: pathway can directly affect the intrinsic one, why do some
- 12:13Speaker 1: studies suggest that blocking MOMP doesn't always prevent cell death?
- 12:17Speaker 1: What's going on there?
- 12:18Speaker 2: Great question. It's about the extent and timing of the interventions.
- 12:22Speaker 2: If you block MOMP too early, you might not fully
- 12:25Speaker 2: stop the process already initiated by the extrinsic pathway. But
- 12:29Speaker 2: if you intervene after significant cytochrome C has been released,
- 12:32Speaker 2: the cell is on its way to apoptosis no matter what.
- 12:35Speaker 1: That's wild when you look at the raw numbers. For instance,
- 12:39Speaker 1: studies show that in certain scenarios, 20% more cell death
- 12:43Speaker 1: can be triggered by FAs compared to the intrinsic pathway. So,
- 12:48Speaker 1: it's not just about the mechanisms, but how they interact.
- 12:52Speaker 2: Exactly. And this isn't just about cancer prevention. The debate
- 12:56Speaker 2: around apoptosis and cancer progression is heated. On one hand,
- 12:59Speaker 2: we know that apoptosis can prevent cancer by eliminating damaged cells.
- 13:04Speaker 2: But under certain conditions … Like chronic oxidative stress, excessive
- 13:09Speaker 2: apoptosis might actually contribute to necrosis, which can promote cancer growth.
- 13:13Speaker 1: So, it's a balancing act, isn't it? Like walking the
- 13:17Speaker 1: tightrope between too much and too little? How do clinicians
- 13:21Speaker 1: and researchers navigate this?
- 13:23Speaker 2: They use a mix of biochemical markers and functional assays
- 13:27Speaker 2: to assess the balance. For example … By monitoring MMP changes,
- 13:32Speaker 2: they can gauge whether the cell is leaning towards or
- 13:35Speaker 2: away from apoptosis. This helps them understand the current state
- 13:39Speaker 2: of the cell and decide on the best intervention strategy.
- 13:42Speaker 1: And this is where precision medicine comes into play. Tailoring
- 13:46Speaker 1: therapies to the specific needs of each patient, based on
- 13:49Speaker 1: these insights, could revolutionize treatment. Whether it's optimizing drugs to
- 13:54Speaker 1: target BCL2 family proteins, or developing new agents to manage
- 13:58Speaker 1: mitochondrial membrane potential. The possibilities are exciting.
- 14:03Speaker 2: Absolutely. The next frontier is identifying non-canonical pathways or alternative
- 14:09Speaker 2: mechanisms that might work in conjunction with the standard ones.
- 14:13Speaker 2: Understanding these will give us more tools to address diseases
- 14:17Speaker 2: like cancer more effectively.
- 14:19Speaker 1: So, as we wrap up, let's remember that apoptosis is
- 14:23Speaker 1: more than just a pathway. It's a complex dynamic process
- 14:26Speaker 1: influenced by multiple factors. And the ongoing debates and nuanced
- 14:30Speaker 1: perspectives from our experts remind us that Tere's still so
- 14:34Speaker 1: much to discover.
- 14:36Speaker 2: Indeed. And that's what makes studying apoptosis so fascinating. Tere's
- 14:40Speaker 2: always something new to unravel.
- 14:42Speaker 1: Right, Rachel? As we look to the future, there are
- 14:45Speaker 1: many unanswered questions and promising directions in the field of
- 14:49Speaker 1: apoptosis research. Take, for instance... the regulation of mitochondrial outer
- 14:54Speaker 1: membrane permeabilization. Mom, we know that BACs and BAC play
- 14:59Speaker 1: crucial roles, but there are still many details to uncover.
- 15:03Speaker 2: Absolutely. The exact mechanisms governing BACs and BACs behavior in
- 15:07Speaker 2: the mitochondrial membrane are still areas of intense debate. For example,
- 15:12Speaker 2: what triggers the translocation of these proteins into the outer membrane?
- 15:16Speaker 2: How do BCL2 proteins interact with BACs and BAC at
- 15:20Speaker 2: the molecular level? to inhibit or promote apoptosis.
- 15:24Speaker 1: That's a great point, Thomas. And when we factor in
- 15:27Speaker 1: non-canonical apoptotic pathways, it becomes even more complex. For instance,
- 15:33Speaker 1: to raise some evidence that RNA molecules might play a
- 15:36Speaker 1: role in regulating apoptosis that isn't fully understood yet.
- 15:40Speaker 2: RNA is fascinating. Let's delve into that. In studies, certain
- 15:44Speaker 2: micronas have been observed to modulate the expression of BCL2
- 15:48Speaker 2: family proteins. For example, Mere negative 155 has been shown
- 15:52Speaker 2: to downregulate BCL2, thereby sensitizing cells to apoptosis. But how
- 15:58Speaker 2: exactly these interactions unfold remains a mystery, especially in the
- 16:02Speaker 2: context of specific diseases like cancer.
- 16:05Speaker 1: Right. Moving on to precision medicine, the ability to tailor
- 16:09Speaker 1: treatments based on individual patient specifics could revolutionize cancer therapy.
- 16:14Speaker 1: For instance … Understanding which patients are more likely to
- 16:18Speaker 1: respond to certain therapeutic interventions based on their apoptosis profile
- 16:23Speaker 1: could significantly improve outcomes.
- 16:25Speaker 2: Indeed, this ties into the idea of stratifying cancer patients
- 16:29Speaker 2: based on their apoptosis status. It's like having a map
- 16:33Speaker 2: that shows the most effective routes to avoid dangerous terrain. Also,
- 16:38Speaker 2: consider the therapeutic potential of targeting BCL-2 family members. Drugs
- 16:43Speaker 2: that inhibit BCL-2 could potentially improve outcomes for patients with
- 16:47Speaker 2: cancers dependent on anti-apoptotic BCL-2 proteins. That's a lot of
- 16:53Speaker 2: untapped potential.
- 16:54Speaker 1: Yes, and in regenerative medicine, the ability to control apoptosis
- 16:59Speaker 1: more precisely could lead to breakthroughs. For example … In diabetes,
- 17:04Speaker 1: understanding how apoptosis affects pancreatic phony cell survival could lead
- 17:09Speaker 1: to therapies that preserve or regenerate these critical cells.
- 17:13Speaker 2: Exactly. In regenerative medicine, the fine balance between apoptosis and
- 17:19Speaker 2: cell survival is crucial. Take, for instance, the retina in
- 17:23Speaker 2: neurodegenerative diseases. If we can find ways to modulate apoptosis
- 17:27Speaker 2: without causing excessive cell death, It could lead to effective
- 17:31Speaker 2: treatments for conditions like age-related macular degeneration.
- 17:35Speaker 1: That's a compelling outlook, Thomas. As researchers continue to peel
- 17:39Speaker 1: back the layers of apoptosis, the potential for new therapies
- 17:43Speaker 1: and interventions becomes clearer. It's an exciting time for medicine,
- 17:47Speaker 1: and we are just scratching the surface. That brings us
- 17:50Speaker 1: to the end of today's episode. Thank you so much
- 17:53Speaker 1: for spending part of your day with me. If you
- 17:55Speaker 1: found this episode's tips helpful, and want to make sure
- 17:58Speaker 1: you don't miss the next conversation, please take a quick
- 18:01Speaker 1: second to hit that subscribe or follow button on whatever
- 18:04Speaker 1: platform you are listening on. It's a completely free way
- 18:08Speaker 1: to support the show and helps more people find us.
- 18:11Speaker 1: This podcast is independently produced, so if you are ever
- 18:14Speaker 1: in a position where you would like to help keep
- 18:16Speaker 1: it running, we do accept small donations. You can find
- 18:20Speaker 1: a link right in the episode description below to buy
- 18:22Speaker 1: us a coffee or contribute what you can. Every bit
- 18:26Speaker 1: genuinely helps. Take care of yourself, stay balanced, and we
- 18:31Speaker 1: will talk again soon.